Al Roker, Type 2 Diabetes, and Insulin: How a Regular Patient Gets Access to Similar Care

What Al Roker Has Said About His Type 2 Diabetes

Al Roker, the longtime "Today" show weatherman, has been candid over the years about his metabolic health. He underwent Roux-en-Y gastric bypass surgery in 2002 and has spoken in interviews and on his own social platforms about the ongoing work of managing his weight and blood sugar. In a 2013 interview with AARP Magazine he described the discipline required to maintain weight loss and glycemic control after surgery. He has not, to public knowledge, provided a detailed current medication list, so any claim that he takes a specific insulin brand or GLP-1 agent by name would be inference and is labeled as such below.

What Bariatric Surgery Does to Blood Sugar

Gastric bypass produces what researchers call "diabetes remission" in a meaningful share of patients. A 2014 meta-analysis published in JAMA Surgery (N=621 studies, 135,246 patients) found that 78.1% of patients with type 2 diabetes experienced complete remission after bariatric surgery, with glycemic improvement often appearing within days, well before substantial weight loss occurs. The mechanism involves changes in gut-hormone signaling, including a dramatic rise in GLP-1 secretion from L-cells in the distal small intestine.

Why Remission Is Not Always Permanent

Remission can last for years, but relapse is common. A landmark Swedish Obese Subjects study followed patients for 10 years and found that roughly 35% of those who had initial remission saw blood glucose levels rise again over time. Weight regain, aging, and declining beta-cell function all contribute. This is almost certainly why Roker has continued to discuss active diabetes management rather than describing himself as cured.

Inference: What Medications He Likely Uses

Given his bariatric history and public statements about ongoing management, a clinician reviewing his publicly available health disclosures would reasonably infer that his regimen involves some combination of lifestyle modification, possibly metformin, and possibly a GLP-1 receptor agonist. This is inference, not confirmed reporting. He has not publicly confirmed a specific prescription. What the clinical literature does confirm is that this combination is standard of care for a post-bariatric patient with persistent or relapsed type 2 diabetes.

The Standard-of-Care Roadmap for Type 2 Diabetes in 2024

Type 2 diabetes management has a clear, evidence-based hierarchy. The American Diabetes Association's 2024 Standards of Medical Care in Diabetes, published in Diabetes Care, organizes treatment by cardiovascular risk, kidney function, weight goals, and A1C target. Understanding this roadmap is the starting point for any patient who wants access to the same quality of care.

Step 1: Lifestyle and Metformin

The ADA 2024 guidelines recommend lifestyle intervention plus metformin as the foundation for most newly diagnosed patients. Metformin lowers A1C by approximately 1.0 to 1.5 percentage points, costs under $10/month as a generic, and has a 60-year safety record. The UKPDS trial, the longest running type 2 diabetes outcomes study, showed that intensive metformin therapy in overweight patients reduced diabetes-related endpoints by 32% compared to conventional treatment over a median 10.7 years of follow-up.

The standard starting dose is 500 mg once daily with the evening meal, titrated over 4 to 8 weeks to a target of 1,000 mg twice daily as tolerated. Gastrointestinal side effects (nausea, loose stools) are common early and usually resolve within 2 to 4 weeks.

Step 2: Adding a GLP-1 Receptor Agonist

When A1C remains above target despite metformin and lifestyle changes, or when a patient has established cardiovascular disease or high cardiovascular risk, the ADA 2024 guidelines recommend adding a GLP-1 receptor agonist or an SGLT-2 inhibitor before escalating to insulin.

Semaglutide (brand name Ozempic for the weekly injectable, Rybelsus for the oral form) is the most studied GLP-1 agent for type 2 diabetes. In the SUSTAIN-6 cardiovascular outcomes trial (N=3,297), once-weekly semaglutide reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 26% versus placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority, P=0.02 for superiority). A1C dropped by a mean of 1.8 percentage points with the 1 mg dose at 104 weeks.

For patients where weight reduction is a co-priority, semaglutide 2.4 mg (Wegovy) delivered 14.9% mean body-weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo. Post-bariatric patients with weight regain and relapsed hyperglycemia are a population where this overlap of glycemic and weight benefit is clinically meaningful.

Step 3: SGLT-2 Inhibitors as an Alternative Add-On

Empagliflozin (Jardiance) and dapagliflozin (Farxiga) are SGLT-2 inhibitors with their own cardiovascular and renal outcome data. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo in patients with type 2 diabetes and established cardiovascular disease. For patients who cannot tolerate GLP-1 agents, SGLT-2 inhibitors are the ADA-recommended alternative second-line class.

Step 4: Basal Insulin

Insulin therapy enters the picture when A1C remains above target on two or more non-insulin agents, or when A1C at diagnosis is above 10 to 11%, suggesting significant beta-cell exhaustion. The most common starting regimen is a long-acting basal insulin: insulin glargine (Basaglar, Lantus, Toujeo) or insulin degludec (Tresiba), started at 10 units subcutaneously at bedtime and titrated by 2 units every 3 days until fasting glucose reaches 80 to 130 mg/dL.

The ADA notes that "many patients with type 2 diabetes will require insulin therapy at some point." Insulin is not a failure. It is a tool, and starting it promptly when indicated reduces the cumulative exposure to hyperglycemia that drives retinopathy, neuropathy, and nephropathy.

How Cardiovascular Risk Changes the Prescription

The 2024 ADA guidelines introduced a significant shift: for patients with established ASCVD (atherosclerotic cardiovascular disease), heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT-2 inhibitor with proven cardiovascular benefit should be added regardless of baseline A1C. This means a patient with well-controlled A1C of 6.9% but a recent MI should still receive semaglutide or empagliflozin, not because of blood sugar but because of organ protection.

The HealthRX clinical team applies a four-axis triage for new type 2 diabetes telehealth patients: (1) current A1C and trend, (2) cardiovascular/renal risk category, (3) weight trajectory and whether a weight-loss benefit is desired, and (4) cost and insurance coverage. These four axes map directly to the ADA's treatment algorithm and allow a prescribing clinician to reach a defensible first prescription within a single 30-minute intake visit. Patients with A1C <8.0% and no high-risk features typically start on metformin alone. Those with A1C 8.0 to 10.0% and ASCVD risk typically receive metformin plus a GLP-1 agent or SGLT-2 inhibitor from visit one. Those presenting with A1C above 10.5% are evaluated for early basal insulin.

What a Real Patient Access Pathway Looks Like

Al Roker has access to elite medical care. His story, however, is not uniquely elite in terms of the medications and protocols available. The same drugs, at the same doses, evaluated by the same guidelines, are accessible to any adult in the United States. Here is exactly how to get there.

Getting a Diagnosis Confirmed

A type 2 diabetes diagnosis requires one of the following, confirmed on two separate occasions unless symptoms are present: fasting plasma glucose of 126 mg/dL or higher, 2-hour glucose of 200 mg/dL or higher during a 75 g oral glucose tolerance test, A1C of 6.5% or higher, or a random plasma glucose of 200 mg/dL or higher with symptoms of hyperglycemia.

Any primary care physician, internist, or endocrinologist can order these tests. A basic metabolic panel (BMP) or a standalone hemoglobin A1C test costs between $15 and $45 at most commercial labs, and many insurance plans cover it with no cost-sharing during an annual wellness visit.

Choosing a Telehealth vs. In-Person Clinician

Telehealth is not a lesser tier of care for type 2 diabetes management. A 2020 systematic review in JMIR Medical Informatics covering 13 randomized controlled trials found that telemedicine-based diabetes management produced A1C reductions equivalent to in-person care, with equivalent medication adjustment rates. For patients in rural areas, or those who cannot take time off work, telehealth removes the single largest barrier to consistent follow-up.

Board-certified endocrinologists and internal medicine physicians can prescribe metformin, GLP-1 receptor agonists, SGLT-2 inhibitors, and basal insulin via telehealth in all 50 states. Controlled substances are not involved, so there are no DEA telehealth prescribing restrictions for standard diabetes drugs.

What to Bring to Your First Appointment

A clinician can write a first prescription for metformin during an initial telehealth visit if you bring: a recent A1C or fasting glucose result (within 3 to 6 months), a basic medication list, and a brief cardiovascular history (any prior heart attacks, strokes, or known coronary artery disease). For GLP-1 agents or SGLT-2 inhibitors, many insurers require documentation of metformin trial or contraindication first. Having that history ready cuts weeks off the prior authorization process.

Cost and Insurance Reality

Metformin is available at Walmart, Costco, and most pharmacy chains for $4, $10 per month without insurance. GLP-1 agents are expensive. Ozempic (semaglutide 0.5 to 2 mg/week) has a list price near $935/month, but Novo Nordisk's patient assistance program covers patients earning under 400% of the federal poverty level. The Novo Nordisk Patient Assistance Program (NovoCare) is available at novocare.com. SGLT-2 inhibitors such as empagliflozin now have generic competitors entering the market and cost $50, $150/month with GoodRx coupons at many pharmacies.

Basal insulin is also subject to a $35/month cap for Medicare beneficiaries under the Inflation Reduction Act of 2022. Many private insurers followed with their own insulin caps, and Eli Lilly and Novo Nordisk both voluntarily reduced list prices for several insulin products to $35/vial in 2023.

Monitoring: What Your Numbers Need to Look Like

Starting a medication is only half the work. The ADA recommends A1C testing every 3 months until the target is reached, then every 6 months once stable. The general A1C target for most non-pregnant adults is <7.0%, though individual targets range from <6.5% in younger patients with long life expectancy and short disease duration to <8.0% in older adults with hypoglycemia unawareness or limited life expectancy.

Home glucose monitoring schedules depend on regimen. Patients on metformin alone do not require routine fasting glucose monitoring but may benefit from weekly spot checks to build awareness. Patients on basal insulin should check fasting glucose daily to guide titration. Continuous glucose monitors (CGMs) such as the Dexterity G7 or the Abbott Libre 3 are now covered by Medicare for all patients with type 2 diabetes using insulin, and by many private plans more broadly.

Annual monitoring should include: urine albumin-to-creatinine ratio (to detect early kidney disease), estimated GFR, a complete lipid panel, and a dilated eye exam. These are not optional. Early diabetic nephropathy is asymptomatic, and the window for intervention with an SGLT-2 inhibitor or ACE inhibitor closes once kidney function has already declined significantly.

The Bariatric Surgery Intersection

For patients with type 2 diabetes and BMI above 35 kg/m2 (or BMI above 30 with poorly controlled diabetes), the ADA 2024 Standards list metabolic and bariatric surgery as a recommended treatment option, not a last resort. The STAMPEDE trial (N=150), published in the New England Journal of Medicine, compared gastric bypass or sleeve gastrectomy to intensive medical therapy and found that 37 to 42% of surgical patients achieved an A1C of 6.0% or lower at 5 years versus 12% in the medical therapy group.

Al Roker's 2002 gastric bypass falls squarely within this evidence base. His experience of sustained but not permanent glycemic improvement also reflects the real-world data. Bariatric surgery is a powerful metabolic tool that reduces A1C, lowers cardiovascular risk, and in many patients eliminates the need for medications for years. Medication therapy remains available and often necessary when the metabolic effects wane.

The Conversation to Have With Your Doctor

The ADA 2024 guidelines include this direct statement: "Diabetes management requires an ongoing, collaborative relationship between the patient and a health-care team that includes physicians, nurses, diabetes care and education specialists, pharmacists, and others." This framing matters. Diabetes is not a condition managed by a physician on your behalf. It is managed by you, with clinical support.

A good first conversation with a prescribing clinician covers four points: your current A1C and whether it is rising or falling, any cardiovascular or kidney risk factors that change which drug class to prioritize, your out-of-pocket cost ceiling, and your preference for injectable versus oral medications. Most patients, when given these options clearly, can reach a treatment plan in a single 30-minute visit.

The ADA also notes that "social determinants of health, including food insecurity, housing instability, and limited English proficiency, affect the ability to manage diabetes and must be assessed and addressed." If cost, food access, or time constraints are barriers, say so at your first visit. There are patient assistance programs, community health workers, and clinical pathways designed specifically for these situations.